What is Remedy Plan?
Remedy Plan Therapeutics is a pioneering small molecule therapeutics startup focused on transforming the field of NAMPT inhibition. The company has developed a groundbreaking, highly tunable hyperbolic inhibition mechanism for NAMPT, which crucially avoids severe on-target toxicity. This innovative approach unlocks therapeutic opportunities for a range of diseases driven by NAMPT dysregulation, including solid tumors, hematologic malignancies, obesity, and autoimmune disorders. Remedy Plan is actively advancing a robust pipeline of these tunable NAMPT inhibitors.
How much funding has Remedy Plan raised?
Remedy Plan has raised a total of $18M across 1 funding round:
Other Financing Round
$18M
Other Financing Round (2025): $18M with participation from Alexandria Venture Investments LLC Alexandria Venture Investments and Schooner Capital
Key Investors in Remedy Plan
Alexandria Venture Investments LLC
Alexandria Venture Investments LLC is a venture capital firm specializing in early-stage investments, likely focusing on companies within the life sciences and biotechnology sectors.
Schooner Capital
Schooner Capital, an established investment firm, provides financial services and investment opportunities, likely supporting companies with growth capital and strategic guidance.
What's next for Remedy Plan?
With this major enterprise-level funding, Remedy Plan Therapeutics is poised for significant expansion and acceleration of its pipeline development. The strategic investment will likely fuel further research and development, clinical trial progression, and the scaling of manufacturing capabilities. The company's focus on addressing a broad spectrum of diseases positions it for substantial market impact, contingent on successful clinical outcomes and regulatory approvals. Future growth will depend on translating its novel mechanism of action into effective treatments for patients.
See full Remedy Plan company page
